Genomic Sequencing Of Tumor Sample Not Patentable, Petitioner Says

(November 27, 2023, 1:13 PM EST) -- ALEXANDRIA, Va. — A cancer diagnostics company accused in Colorado federal court of infringing a method of screening for cancer recurrence maintains in a Nov. 22 filing with the Patent Trial and Appeal Board that the patent asserted against it should be canceled as anticipated and obvious....

Attached Documents

Related Sections